Q BioMed Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a QBIO research report →
Price Chart
About the company
Q BioMed Inc. functions as a biomedical accelerator and developer, actively licensing, acquiring, and supplying resources to firms within the life sciences and healthcare sectors. Its commercial portfolio includes Metastron (Strontium Chloride SR89), a radiopharmaceutical designed to alleviate pain associated with metastatic bone cancer.
- CEO
- Denis D. Corin
- IPO
- 2015
- Employees
- 3
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on QBIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $14.51K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.05
- P/B
- -0.00
- EV/EBITDA
- -6.60
- Div Yield
- 0.00%
- Gross Margin
- -3.16%
- Op Margin
- -1211.74%
- Net Margin
- -721.67%
- ROE
- 44.12%
- ROIC
- 679.02%
Latest fiscal year · YoY change
- Revenue
- $284.35K+45.4%
- Gross Profit
- $-8,988+82.5%
- Op Income
- $-3,445,616
- Net Income
- $-2,052,093+75.1%
- EPS
- $-0.08+76.3%
- OCF Growth
- +145.1%
- FCF Growth
- +145.1%
- 52W High
- $0.03
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -154.93
- RSI (14)
- 52
- Avg Volume
- 376
No earnings-call transcripts are available for QBIO yet.
- Free Float
- 97.1%
- Shares Outstanding
- 145.09M
- Float Shares
- 140.88M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 26, 22 | Corin Denis | other | 200,000 |
| Feb 1, 21 | Rosenstadt William S | other | 35,000 |
| Oct 27, 20 | Corin Denis | other | 500,000 |
| Aug 29, 20 | Corin Denis | other | 150,000 |
| Aug 29, 20 | Corin Denis | other | 150,000 |
| Oct 27, 20 | Rosenstadt William S | other | 500,000 |
| Aug 29, 20 | Rosenstadt William S | other | 150,000 |
| Aug 29, 20 | Rosenstadt William S | other | 150,000 |
| Apr 6, 20 | Rosenstadt William S | other | 225,000 |
| Feb 10, 20 | Corin Denis | other | 750,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our QBIO coverage
Recent articles, reports, and earnings notes.
No research on QBIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate QBIO report →Q Biomed (OTCMKTS:QBIO) vs. GeneDx (NASDAQ:WGS) Financial Comparison
defenseworld.net · Apr 5
Establishment Labs (NASDAQ:ESTA) & Q Biomed (OTCMKTS:QBIO) Critical Contrast
defenseworld.net · Feb 10
Q Biomed (OTCMKTS:QBIO) & Auna (NYSE:AUNA) Head to Head Review
defenseworld.net · Jan 19
Q Biomed (OTCMKTS:QBIO) & GoodRx (NASDAQ:GDRX) Financial Survey
defenseworld.net · Jan 3
SBC Medical Group (NASDAQ:SBC) and Q Biomed (OTCMKTS:QBIO) Head-To-Head Contrast
defenseworld.net · Dec 10
Q BioMed receives US patent and notice of allowance in Europe for Uttroside B; seeks ways to boost shareholder value
proactiveinvestors.com · Apr 14
Q BioMed gets notice of allowable US patent for liver cancer treatment Uttroside B
proactiveinvestors.com · Feb 10
Q BioMed boosted by multi-million dollar asset as it converts long-term royalty into equity stake in Mannin Research
proactiveinvestors.ca · Nov 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.